Provided by Tiger Trade Technology Pte. Ltd.

Haemonetics

102.69
+1.631.61%
Post-market: 102.690.00000.00%19:30 EDT
Volume:458.31K
Turnover:46.77M
Market Cap:4.67B
PE:50.09
High:102.89
Open:101.70
Low:100.53
Close:101.06
52wk High:109.57
52wk Low:47.32
Shares:45.45M
Float Shares:44.60M
Volume Ratio:0.81
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.05
EPS(LYR):2.05
ROE:11.20%
ROA:6.60%
PB:5.58
PE(LYR):50.09

Loading ...

Does CHAPTER-3 Enrollment Milestone and Pipeline Progress Change The Bull Case For Pharvaris (PHVS)?

Simply Wall St.
·
Apr 05

Press Release: Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Dow Jones
·
Apr 02

Haemonetics sets earnings release, conference call for fiscal Q4, full-year results

Reuters
·
Apr 02

Haemonetics wins FDA label expansion for VASCADE MVP XL venous closure system

Reuters
·
Mar 31

Haemonetics Receives FDA Approval for Expanded Labeling of the Vascade Mvp® Xl Venous Vascular Closure System

THOMSON REUTERS
·
Mar 31

A Look At Haemonetics (HAE) Valuation After Recent Share Price Weakness

Simply Wall St.
·
Mar 27

Sustained EKTERLY Uptake and Shift Toward Oral HAE Therapy Underpin Buy Rating on KalVista

TIPRANKS
·
Mar 26

Italy's GVS FY revenue rises on healthcare & life sciences strength

Reuters
·
Mar 26

Here's one reason why experts think the CSL share price can rise 65%!

MotleyFool
·
Mar 26

Press Release: KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update

Dow Jones
·
Mar 25

Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology

GlobeNewswire
·
Mar 20

Is New HAE Patient-Reported Outcome Study Altering The Investment Case For Pharvaris’ Deucrictibant (PHVS)?

Simply Wall St.
·
Mar 17

Takeda’s New South Korea HAE Study Aims to Cement Takhzyro’s Real World Edge

TIPRANKS
·
Mar 14

Takeda’s EXPLORHAE HAE Study in Egypt: Real‑World Data With Long‑Term Investor Upside

TIPRANKS
·
Mar 14